Treatment for COVID-19: An overview
Abstract Coronavirus disease 2019 (COVID-19) is an infectious disease caused by
coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a …
coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a …
[HTML][HTML] Risk of venous thromboembolism in patients with COVID‐19: a systematic review and meta‐analysis
Background Venous thromboembolism (VTE) is frequently observed in patients with
coronavirus disease 2019 (COVID‐19). However, reported VTE rates differ substantially …
coronavirus disease 2019 (COVID‐19). However, reported VTE rates differ substantially …
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with …
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with …
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
Background Real-world evidence on the association between autoimmune inflammatory
rheumatic diseases, therapies related to these diseases, and COVID-19 outcomes are …
rheumatic diseases, therapies related to these diseases, and COVID-19 outcomes are …
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and …
R Hasseli, U Mueller-Ladner, BF Hoyer, A Krause… - RMD open, 2021 - rmdopen.bmj.com
Introduction Whether patients with inflammatory rheumatic and musculoskeletal diseases
(RMD) are at higher risk to develop severe courses of COVID-19 has not been fully …
(RMD) are at higher risk to develop severe courses of COVID-19 has not been fully …
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
J Loarce-Martos, A García-Fernández… - Rheumatology …, 2020 - Springer
The objective of this study is to describe the characteristics and outcomes of rheumatic and
musculoskeletal disease (RMD) patients who were treated with rituximab and had …
musculoskeletal disease (RMD) patients who were treated with rituximab and had …
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease
R Fernandez-Ruiz, JL Paredes, TB Niewold - Translational Research, 2021 - Elsevier
As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …
Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave
ERA Vos, G den Hartog, RM Schepp… - J epidemiol community …, 2021 - jech.bmj.com
Background We aimed to detect SARS-CoV-2 serum antibodies in the general population of
the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic …
the Netherlands and identify risk factors for seropositivity amidst the first COVID-19 epidemic …
Clinical outcomes of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis of global data
Objectives The impact of rheumatic diseases on COVID-19 infection remains poorly
investigated. Here we performed a systematic review and meta-analysis to evaluate the …
investigated. Here we performed a systematic review and meta-analysis to evaluate the …